Humana is higher today as investors react to a company update that reaffirmed its full-year earnings outlook and indicated its preliminary 2026 Medicare Advantage Star Ratings are in line with assumptions used in its financial planning. With Star Ratings directly influencing bonus payments and plan economics, confirmation that ratings are tracking expectations helped ease concerns about further downside surprises after earlier guidance volatility.

For Medicare Advantage-heavy insurers, modest shifts in Star Ratings can have outsized impacts on revenue and margins because they affect quality bonus payments and rebate levels. By signaling that preliminary Star Ratings are not creating an incremental headwind versus plan assumptions, the update supports the view that the company can execute within its existing multi-year framework rather than needing another reset.

Humana was up roughly 3% near $230, aligning with a broader relief bid seen when insurer-specific uncertainty around guidance and Medicare Advantage profitability diminishes. The move extends a bounce from recent lows, though the stock remains well below prior-year levels, keeping investors focused on follow-through catalysts rather than a single-day reaction.